###begin article-title 0
###xml 54 60 54 56 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
EP2 receptor mediated cAMP release is augmented by PGF2alpha activation of the FP receptor via the calcium-calmodulin pathway
###end article-title 0
###begin p 1
This document may be redistributed and reused, subject to .
###end p 1
###begin title 2
Abstract
###end title 2
###begin p 3
###xml 1030 1032 1030 1032 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 1616 1617 1612 1613 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q</sub>
###xml 1620 1622 1616 1618 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
Prostaglandins exert their effects on target cells by coupling to specific G protein-coupled receptors (GPCRs) that are often co-expressed in the same cells and use alternate and in some cases opposing intracellular signaling pathways. This study investigated the cross-talk that influences intracellular signaling and gene expression profiling in response to co-activation of the EP2 and FP prostanoid receptors in Ishikawa cells stably expressing both receptors (FPEP2 cells). In this study we show that in FPEP2 cells, PGF alone does not alter adenosine 3',5'-cyclic monophosphate (cAMP) production, but in combination with Butaprost enhances EP2 receptor mediated cAMP release compared to treatment with Butaprost alone. PGF-mediated potentiation of cAMP release was abolished by antagonism of the FP receptor, inhibition of phospholipase C (PLC) and inositol phosphate receptor (IP3R) whereas inhibition of protein kinase C (PKC) had no effect. Moreover, inhibition of calcium effectors using calmodulin antagonist (W7) or Ca2+/calmodulin-dependent kinase II (CaMK-II) inhibitor (KN-93) abolished PGF potentiation of Butaprost-mediated cAMP release. Using siRNA molecules targeted against the adenylyl cyclase 3 (AC3) isoform, we show that AC3 is responsible for the cross-talk between the FP and EP2 receptors. Using gene array studies we have identified a candidate gene, Spermidine/N1-acetyltransferase (SAT1), which is regulated by this cAMP mediated cross-talk. In conclusion, this study demonstrates that co-activation of the FP and EP2 receptors results in enhanced release of cAMP via FP receptor-Galphaq-Ca2+-calmodulin pathway by activating calcium sensitive AC3 isoform.
###end p 3
###begin title 4
Abbreviations
###end title 4
###begin title 5
Keywords
###end title 5
###begin title 6
Introduction
###end title 6
###begin p 7
###xml 146 147 146 147 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 155 161 155 157 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
###xml 305 310 301 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib1 bib2" ref-type="bibr">[1,2]</xref>
###xml 479 484 475 480 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib3 bib4 bib5" ref-type="bibr">[3&#8211;5]</xref>
###xml 287 292 <span type="species:ncbi:9606">human</span>
Prostaglandins exert paracrine and autocrine effects on target cells by coupling to their specific GPCRs and activate intracellular signaling. PGE2 and PGF2alpha (PGF) are the most abundantly biosynthesized prostaglandins and are major metabolites of cyclooxygenase (COX) enzymes in the human endometrium [1,2]. Furthermore, COX enzyme expression, prostaglandins synthesis and their cognate receptors expression (mainly EP2 and FP) are dysregulated in endometrial adenocarcinoma [3-5].
###end p 7
###begin p 8
###xml 144 146 140 142 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">s,</sub>
###xml 224 225 216 217 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q</sub>
###xml 321 328 313 320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib1 bib6 bib7 bib8" ref-type="bibr">[1,6&#8211;8]</xref>
###xml 670 676 662 668 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib9 bib10" ref-type="bibr">[9,10]</xref>
###xml 772 773 760 761 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i</sub>
###xml 779 788 767 769 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;&#947;</sub>
###xml 1011 1018 992 999 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1018 1025 999 1006 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib10 bib11" ref-type="bibr">[10,11]</xref>
###xml 1112 1113 1089 1090 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">s</sub>
###xml 1120 1121 1093 1094 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q</sub>
###xml 1177 1184 1150 1157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib12 bib13 bib14" ref-type="bibr">[12&#8211;14]</xref>
###xml 1213 1217 1186 1190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib13" ref-type="bibr">[13]</xref>
###xml 1369 1370 1332 1333 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q</sub>
EP2 and FP receptors are often co-expressed in the same cells and use different intracellular signaling pathways. EP2 receptors couple to Galphas, resulting in increased formation of cAMP, while FP receptors couple to Galphaq which in turn results in release of inositol-1,4,5-triphosphate (IP) and dialcylglycerol (DAG) [1,6-8]. cAMP is generated in cells from adenosine triphosphate (ATP) by the enzymatic activity of the adenylyl cyclase (AC) family members. There are multiple AC isoforms (9 membrane-bound and 1 soluble) with different amino acid sequence, tissue distribution and regulation. AC isoforms are named from AC1 to AC9 in the order of their publication [9,10]. Difference in regulation of these isoforms includes sensitivity to calcium, G proteins (Galphai and Gbetagamma), protein kinases (PKA, PKC, calmodulin and calmodulin-kinase) and phosphatases (calcineurin). Out of the ten AC isoforms three (AC1, AC3 and AC8) are calcium stimulated while AC5 and AC6 are normally inhibited by calcium in vivo[10,11]. The intracellular calcium pathway has been shown to play a significant part in Galphas-Galphaq cross-talk by regulating calcium sensitive AC isoforms [12-14]. For example, Ostrom et al. [13] showed a potentiation of beta-adrenergic (beta-AR) receptor induced cAMP production by activation of angiotensin II (ANG-II) receptor coupled to Galphaq protein through calcium/calmodulin pathway demonstrating cross-talk between ANG-II and beta-AR receptors in cardiac fibroblasts cells.
###end p 8
###begin p 9
###xml 95 99 95 99 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib15" ref-type="bibr">[15]</xref>
###xml 141 142 141 142 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 474 478 460 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib16" ref-type="bibr">[16]</xref>
###xml 512 516 498 502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib17" ref-type="bibr">[17]</xref>
###xml 569 574 <span type="species:ncbi:9606">human</span>
GPCR cross-talk in the eicosaniod family has been shown in several studies. Walsh and Kinsella [15] showed a cross-talk between thromboxane A2 (TPalpha and TPbeta) and EP1 receptors in HEK 293 cells that leads to desensitization and inhibition of signaling of the TP receptors in a PKC-dependent manner. The same group further indentified that the activation of the FP receptor by PGF can also mediate desensitization of the TPalpha and TPbeta receptors via the PKC pathway [16]. In another study, Wilson et al. [17] showed that heterodimerzation can occur between the human receptors for prostacyclin (IP) and TPalpha that leads to augmentation of TPalpha receptors-mediated accumulation of cAMP by IP receptors when they are co-expressed in a HEK 293 cell line.
###end p 9
###begin p 10
###xml 80 86 80 86 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib7 bib18" ref-type="bibr">[7,18]</xref>
Since EP2 and FP receptors are co-expressed in endometrial adenocarcinoma cells [7,18], this study investigated the cross-talk that may influence intracellular signaling and target gene activation in response to co-activation of EP2 and FP receptors.
###end p 10
###begin title 11
Materials and methods
###end title 11
###begin title 12
Reagents
###end title 12
###begin p 13
###xml 933 934 925 926 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q</sub>
All chemicals used were molecular biology grade and were obtained from Sigma (Dorset, UK or RSA) or IBI (Cambridge, UK). Cell culture media was purchased from Gibco (Gibco, Paisely, UK). Hygromycin (100 mg/ml stock) was purchased from Invitrogen (Invitrogen, Autogen Bioclear UK) while G418 (100 mg/ml stock in PBS), indomethcin (3 mg/ml stock in ethanol), Butaprost (5 mM stock in ethanol), PGF (100 microM stock in ethanol) and 3-isobutyl-1-methyl xanthine (IBMX, 20 mM stock in 50% ethanol) were purchased from Sigma (Sigma chemical Co., Nottingham, UK). FP receptor antagonist (AL8810, 50 mM stock in ethanol), IP3R blocker (2-APB, 40 mM stock in DMSO), PLC inhibitor (U73122, 10 mM stock in DMSO), calmodulin antagonist (W7, 25 mM stock in DMSO), CaMK-II inhibitor (KN-93, 50 mM stock in DMSO) and PKC inhibitor (Ro-31-822, 1 mM stock in DMSO) were all purchased from Calbiochem (Calbiochem, Nottingham, UK). Inhibitor of Galphaq (YM254890, 1 mM stock in DMSO) was a kind gift from M. Taniguchi, (Astellas Pharmaceuticals Inc., Tokyo, Japan). The EP2 and FP receptor primary antibodies were purchased from Cayman Chemical Company (Axxora, Nottingham, UK) and primary antibody for actin was purchased from Santa Cruz Biotechnology (Santa Cruz, Wiltshire, UK). Fluorescent secondary antibodies were purchased from Li-Cor Biosciences (Li-Cor Biosciences, Cambridge, UK). Stealth siRNA duplex oligoribonucleotides for AC1 and AC3 were purchased from Invitrogen (Invitrogen, Paisley, UK).
###end p 13
###begin title 14
Cell culture
###end title 14
###begin p 15
###xml 55 59 55 59 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib18" ref-type="bibr">[18]</xref>
Ishikawa cells were maintained as described previously [18]. FPEP2 clones were maintained in G418 and hygromycin (200 microg/ml each) to select for the expression of FP and EP2 receptor, respectively.
###end p 15
###begin title 16
EP2 receptor amplification and stable cell line transfection
###end title 16
###begin p 17
###xml 166 169 166 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib7" ref-type="bibr">[7]</xref>
###xml 171 174 171 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib6" ref-type="bibr">[6]</xref>
###xml 252 255 252 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib6" ref-type="bibr">[6]</xref>
###xml 554 557 554 555 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#174;</sup>
To make stable cell lines expressing both EP2 and FP receptors, Ishikawa cells stably expressing the FP receptor (FPS32 cell lines) were used as a parental cell line [7]. [6]. cDNA from proliferative endometrium was synthesised as previously described [6] and EP2 receptor was amplified using forward 5'-TCTCTTTTCCAGGCACCCCAC-3' and reverse 5'-TTTTAAACTGACCTCAAAGGTCAGC-3' primers. EP2 receptor cDNA was ligated into the pcDNA3.1 (Invitrogen) expression vector in both sense and antisense directions and was transfected to the FPS32 cells using SuperFect(R) transfection reagent (QIAGEN, UK) according to manufacturer's recommendations. Transfected cells were selected in a medium containing 800 microg/ml of hygromycin in parallel with untransfected cells. Once untransfected cells had died, hygromycin-resistant clones were picked and expanded under the selective medium. Clones were then screened for the expression of the EP2 receptor by quantitative real-time RT-PCR and for their ability to produce intracellular cAMP in response to Butaprost treatment. Three FPEP2 clones (clones 4, 8 and 10) with similar expression levels and biochemical characteristics were selected for further investigation. Data on FPEP2 clone 8 is presented here, with similar data obtained using the other two clones.
###end p 17
###begin title 18
cDNA synthesis and real-time RT-PCR
###end title 18
###begin p 19
###xml 194 198 194 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib18" ref-type="bibr">[18]</xref>
###xml 366 373 366 373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="tbl1" ref-type="table">Table&#160;1</xref>
###xml 399 403 399 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib18" ref-type="bibr">[18]</xref>
Total RNA was extracted from Ishikawa cells using Tri-Reagent (Sigma-Aldrich Corp., Poole, UK) as manufacturer's recommendations and cDNA was synthesised from total mRNA as described previously [18]. Thereafter, quantitative real-time RT-PCR was performed with specific E and F prostanoid (EP1, EP2, EP3, EP4 and FP receptors), AC1, AC3 and SAT1 primers and probes (Table 1) as described previously [18]. Expression of analyzed genes was normalized to RNA loading for each sample using the 18S ribosomal RNA as an internal standard. Results are expressed as fold increase above vehicle treated cells. Data are presented as mean +/- SEM from at least 3 independent experiments.
###end p 19
###begin title 20
Protein extraction from cells, SDS-PAGE and western blotting
###end title 20
###begin p 21
###xml 49 50 49 50 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 162 166 162 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib18" ref-type="bibr">[18]</xref>
###xml 221 222 221 222 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sub>
###xml 571 575 564 568 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib18" ref-type="bibr">[18]</xref>
###xml 998 999 979 980 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">.</italic>
###xml 605 611 <span type="species:ncbi:9986">rabbit</span>
###xml 656 660 <span type="species:ncbi:9925">goat</span>
###xml 820 826 <span type="species:ncbi:9793">donkey</span>
###xml 832 838 <span type="species:ncbi:9986">rabbit</span>
###xml 890 896 <span type="species:ncbi:9793">donkey</span>
###xml 902 906 <span type="species:ncbi:9925">goat</span>
Ishikawa cells were seeded at a density of 5 x 105 cells in 6 cm dishes overnight. The following day protein was extracted from the cells as described previously [18]. Total protein was quantified using standard BIO-RAD DC assay (Bio-Rad, Hemel Hempstead, UK) as directed by the manufacturer's instruction. A total of 40 mug of protein was resuspended in 1x Laemmli buffer (125 mM Tris-HCL pH 6.8, 4% SDS, 20% glycerol, 5% 2-mercapthoethanol and 0.05% bromophenol blue) and boiled for 5 min at 95 degreesC. Samples were resolved and immunoblotted as described previously [18] prior to incubating with the rabbit anti-EP2 or FP receptor in combination with goat anti-actin primary antibody (all in 1:1000) at 4 degreesC overnight. The membrane was then washed with PBS-Tween and incubated with the secondary fluorescence donkey anti-rabbit IgG conjugated to Alexa Fluor 680 (Invitrogen) and donkey anti-goat IgG conjugated to IRDYE 800 (Tebu-bio, Peterborough, UK) for 1 h in the dark at 25 degreesC. After washing the membrane proteins were then viewed using Odyssey Infrared imaging system (Li-Cor Bioscience, Cambridge, UK).
###end p 21
###begin title 22
Immunofluorescence microscopy of cells
###end title 22
###begin p 23
###xml 143 147 143 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib19" ref-type="bibr">[19]</xref>
###xml 404 408 <span type="species:ncbi:9925">goat</span>
###xml 478 484 <span type="species:ncbi:9986">rabbit</span>
###xml 537 541 <span type="species:ncbi:9925">goat</span>
###xml 678 682 <span type="species:ncbi:9925">goat</span>
###xml 688 694 <span type="species:ncbi:9986">rabbit</span>
The site of EP2 and FP receptor expression in FPS32 and FPEP2 cells were localised using immunofluorescence microscopy as described previously [19]. Briefly, 100,000 cells/well were plated out in 2-well cell chamber slides and left to adhere overnight. The next day cells were fixed with ice-cold 4% paraformaldehyde (PFA) for 20 min and washed with PBS, before being blocked by 5% BSA diluted in normal goat serum for 2 h. Thereafter, the cells were incubated with polycolonal rabbit anti-EP2 and FP receptor antibody diluted in normal goat serum (1:100) overnight at 4 degreesC. The next day, cells were washed three times in PBS for 10 min and incubated with Alexa Flour 488 goat anti-rabbit IgG (1:200 in PBS; Molecular Probes) for 2 h. Slides were counterstained with DAPI (1:1000 in PBS; Sigma) for 10 min for nuclear visualisation, washed and mounted in Permafluor (Immunotech-Coulter, Buckinghamshire, United Kingdom) and coverslipped for microscopic analysis. Control cells were incubated with preadsorbed primary antibodies with a specific immunogen blocking peptide.
###end p 23
###begin title 24
Ligand stimulation and cAMP assay
###end title 24
###begin p 25
###xml 79 80 79 80 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
Butaprost and/or PGF-induced cAMP accumulation was determined by seeding 2 x 105 Ishikawa cells/well in 6-well plates. The cells were serum-starved in the presence of 3 microg/ml of indomethacin (a dual Cox enzyme inhibitor used to inhibit production of endogenous prostaglandins). Thereafter, the cells were pre-treated with the phosphodiesterase inhibitor IBMX (Sigma) to a final concentration of 0.2 mM in serum-free medium for 30 min. Cells were treated for 5 min with vehicle, Butaprost (5 microM) and/or PGF (100 nM) in the presence/absence of different chemical inhibitors as described in the figure legends. After incubation the cells were lysed in R&D Cell Lysis Buffertrade mark (R&D Systems, Oxford UK) and cAMP release was determined by ELISA using cAMP Kit (R&D Systems) according to manufacturer's protocol. The concentration of cAMP was calculated using a standard curve by Assay Zap (Biosoft, Cambridge, UK) and was normalized according to the respective protein concentration of each sample. Data are represented as mean +/- SEM.
###end p 25
###begin title 26
Total inositol phosphate (IP) assay
###end title 26
###begin p 27
###xml 87 91 87 91 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib20" ref-type="bibr">[20]</xref>
###xml 264 265 260 261 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 739 740 729 730 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 375 379 <span type="species:ncbi:9913">calf</span>
PGF and/or Butaprost-induced accumulation of IP was determined as previously described [20]. Briefly, Ishikawa cells (50,000 cells/well) were seeded in 24-well plates and allowed to adhere overnight. The following day, cells were labeled with 0.5 microCi/well myo-3H-inositol (Amersham Bioscineces, RSA) in an inositol-free DMEM 199 media supplemented with 2% dialyzed fetal calf serum overnight. The next day, cells were stimulated with PGF and/or Butaprost with the required concentration for an hour at 37 degreesC while non-stimulated samples were taken as control for each experiment. After aspirating the buffer, cells were lysed by the addition of 1 ml ice-cold 10 mM formic acid and the plates were placed on ice for 30 min. Total 3H-inositol phosphates were separated from cell extracts on AG 1-X8 resin by anion exchange chromatography and counted by scintillation counting in Liquid Scintillation Analyzer (Packard GmbH, Frankfurt, Germany). Data are represented as mean +/- SEM and expressed as fold increase above non-stimulated samples.
###end p 27
###begin title 28
Knockdown of AC1 and AC3 with siRNA transfection
###end title 28
###begin p 29
###xml 191 192 191 192 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 416 419 416 417 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#174;</sup>
Three different Stealth siRNA duplex oligoribonucleotides (Invitrogen, Paisley, UK) were used to abolish the expression and function of AC1 and AC3. FPEP2 Ishikawa cells were seeded (7.5 x 104 cells/well) in complete media into 12-well plates. On the day of the transfection, the cells were exposed to 60 nM (20 nM from each Stealth siRNA) AC isoform-specific or scrambled sequence siRNA in the presence of SuperFect(R) (QIAGEN, Crawley, UK) for 6 h. After 48 h of transfection the cells were subjected to RNA extraction for AC1 and AC3 mRNA expression analysis or serum-starved overnight in medium containing indomethacin (3 microg/ml) for cAMP assay. For cAMP assay, cells were then exposed to either Butaprost (5 microM) and/or PGF (100 nM) for 5 min, lysed and subjected to cAMP analysis as described earlier.
###end p 29
###begin title 30
Gene array and data analysis
###end title 30
###begin p 31
###xml 55 56 55 56 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 318 319 310 311 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1058 1062 1050 1054 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib21" ref-type="bibr">[21]</xref>
###xml 1182 1186 1174 1178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib22" ref-type="bibr">[22]</xref>
###xml 1192 1193 1184 1185 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1271 1275 1263 1267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib23" ref-type="bibr">[23]</xref>
###xml 1377 1378 1369 1370 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1455 1459 1447 1451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib24" ref-type="bibr">[24]</xref>
###xml 758 763 <span type="species:ncbi:9606">Human</span>
Ishikawa FPEP2 cells were seeded at a density of 5 x 105 cells, serum-starved for 18 h in the presence of 3 microg/ml of indomethacin. Cells were then treated in serum-free media for 8 h with vehicle, Butaprost (5 microM) and/or PGF (100 nM). Treatments were performed in triplicate and repeated four times, (total of n = 12 for each treatment). After treatment, the cells were washed with ice-cold PBS, total RNA was extracted from each sample, RNA was analyzed and triplicates pooled to produce four samples of each treatment for array analysis. RT-IVT was then carried out in accordance to the Applied Biosystems Chemiluminescent RT-IVT nanoamp (one-cycle) labelling protocol. Samples were fragmented and hybridized to AB1700 version 2 Applied Biosystems Human Genome Survey microarrays. After hybridization the GeneChip arrays were stained and washed on the fluidics station and scanned. Data acquired using ABI technology was pre-processed according to the manufacturers' recommendations. The data was normalized using variance stabilized normalization [21]. Normalized data were analyzed for differential expression with the LIMMA package as described in the LIMMA user guide [22]. The P values were adjusted for multiple testing with Benjamini and Hochberg method [23]. The resulting gene list included only the genes that had a fold change value of 2.0 or higher and a P of <0.05. Bioinformatics was performed using the gene set analysis tool kit [24]. A hypergeometric test was used to calculate significantly overrepresented ontologies from the gene list. Array hybridization and data analysis was performed by GeneService Ltd (Cambridge, UK). Gene Ontology annotations were assigned to classify Butaprost and/or PGF regulated genes for biological processes and molecular functions using a web tool provided by the gene ontology database ().
###end p 31
###begin title 32
Statistical analysis
###end title 32
###begin p 33
###xml 195 196 193 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 209 210 207 208 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 225 226 223 224 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
All data are presented as mean +/- S.E.M. Statistical significant differences were determined by one-way analysis of variance using Prism 5.0 software (GraphPad Software Inc., San Diego, CA) (*, P < 0.05; **, P < 0.001; ***, P < 0.0001).
###end p 33
###begin title 34
Results
###end title 34
###begin title 35
EP2 and FP receptor expression in stably transfected Ishikawa cells
###end title 35
###begin p 36
###xml 350 356 350 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig1" ref-type="fig">Fig.&#160;1</xref>
###xml 480 481 480 481 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 642 648 642 648 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig1" ref-type="fig">Fig.&#160;1</xref>
###xml 675 681 675 681 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig1" ref-type="fig">Fig.&#160;1</xref>
###xml 719 725 719 725 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig1" ref-type="fig">Fig.&#160;1</xref>
In order to investigate the cross-talk between the EP2 and FP receptors, we created a stable cell line expressing the EP2 and FP receptor in Ishikawa cells (FPEP2 cells). We initially assessed the expression of the E prostanoid receptors (EP1, EP2, EP3 and EP4) and FP receptor in FPEP2 cells in comparison with the parental FPS32 cells. As shown in Fig. 1A, quantitative real-time RT-PCR revealed a significant increase of EP2 receptor expression above the parental FPS32 cells (P < 0.0001). There was no significant difference in expression of EP1, EP3, EP4 and the FP receptor between the FPEP2 cell line and the parental FPS32 cell line (Fig. 1B). Western blot analysis (Fig. 1C) and immunofluorescence microscopy (Fig. 1D) confirmed elevated expression of EP2 receptor protein in the FPEP2 cells compared to the FPS32 cells while the FP receptor expression was not altered between the two cell lines.
###end p 36
###begin p 37
###xml 88 92 88 92 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib25" ref-type="bibr">[25]</xref>
###xml 297 303 296 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig1" ref-type="fig">Fig.&#160;1</xref>
###xml 419 420 418 419 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 433 434 432 433 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 640 646 639 645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig1" ref-type="fig">Fig.&#160;1</xref>
Activation of the EP2 receptor by Butaprost leads to intracellular accumulation of cAMP [25]. In order to assess the functionality of the EP2 receptor in FPEP2 cells, the ability to generate cAMP was determined by treating the cells with vehicle or Butaprost (5 muM) for 5 and 10 min. As shown in Fig. 1E, treatment of FPEP2 cells with Butaprost for 5 or 10 min increased intracellular cAMP accumulation significantly (P < 0.001 and P < 0.0001, respectively) in a time-dependent manner compared to vehicle treatment. Butaprost treatment of the FPS32 cell line had no effect on intracellular cAMP accumulation compared to vehicle treatment (Fig. 1E).
###end p 37
###begin p 38
###xml 27 28 23 24 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q</sub>
###xml 118 122 114 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib25" ref-type="bibr">[25]</xref>
###xml 296 300 292 296 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;&#160;10</sup>
###xml 306 309 302 305 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;&#160;6</sup>
###xml 380 386 376 382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig1" ref-type="fig">Fig.&#160;1</xref>
###xml 499 500 495 496 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</italic>
###xml 500 503 496 499 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">max</sub>
###xml 552 554 544 546 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 679 685 667 673 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig1" ref-type="fig">Fig.&#160;1</xref>
The FP receptor is a Galphaq-coupled receptor, which upon PGF activation leads to an accumulation of intracellular IP [25]. In order to compare the functionality of the FP receptors in the parental FPS32 and FPEP2 cell lines, the cells were subjected to increasing doses of PGF administration (10- 10 to 10- 6 M) while control samples were left untreated for an hour. As shown in Fig. 1F, PGF treatment of both the parental FPS32 and FPEP2 cells gave a dose-dependent increase in IP release with an Emax value of 15.7 +/- 0.6 and 16.6 +/- 2.1 and an EC50 value of 2.3 nM +/- 0.3 and 1.95 nM +/- 0.8 for the FPS32 and FPEP2 cell lines respectively, confirming our observations in Fig. 1B and C, that the levels of FP receptor were similar between the FPS32 and FPEP2 cells.
###end p 38
###begin title 39
###xml 75 76 71 72 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q</sub>
PGF potentiates Butaprost-stimulated cAMP production via FP receptor-Galphaq coupling and PLC activation in FPEP2 Ishikawa cells
###end title 39
###begin p 40
###xml 163 167 163 167 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;&#160;10</sup>
###xml 173 176 173 176 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;&#160;6</sup>
###xml 220 224 219 223 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;&#160;10</sup>
###xml 230 233 229 232 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;&#160;6</sup>
###xml 282 288 280 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig2" ref-type="fig">Fig.&#160;2</xref>
###xml 449 450 447 448 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</italic>
###xml 450 453 448 451 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">max</sub>
###xml 471 472 467 468 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</italic>
###xml 472 475 468 471 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">max</sub>
###xml 498 500 492 494 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 838 844 827 833 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig2" ref-type="fig">Fig.&#160;2</xref>
###xml 978 979 967 968 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1194 1200 1183 1189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig2" ref-type="fig">Fig.&#160;2</xref>
###xml 1203 1204 1192 1193 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
We next determined the integrated effect of Butaprost and PGF co-administration on IP and cAMP release. FPEP2 cells were treated with an increasing dose of PGF (10- 10 to 10- 6 M) or 5 muM Butaprost alone or with PGF (10- 10 to 10- 6 M) and 5 muM of Butaprost together. As shown in Fig. 2A, Butaprost treatment of the FPEP2 cells had no effect on IP release, since treatment of PGF alone or in combination with Butaprost gave a similar IP response (Emax 15.5 +/- 0.6 and Emax of 16.6 +/- 2.2 and EC50 0.7 nM +/- 0.5 and 1.95 +/- 1.04, respectively). These data demonstrate that PGF-mediated IP release is not affected by Butaprost treatment. To assess the effect of FP receptor induction by PGF on Butaprost-stimulated cAMP accumulation, FPEP2 cells were treated with vehicle, Butaprost (5 muM) and/or PGF (100 nM) for 5 min. As shown in Fig. 2B, treatment of cells with Butaprost alone gave a robust increase in intracellular cAMP accumulation compared with vehicle treatment (P < 0.001), while treatment with PGF alone had minimal effect. However, co-treatment of the cells with Butaprost and PGF together significantly increased the cAMP response compared to treatment with Butaprost alone (Fig. 2B; P < 0.001).
###end p 40
###begin p 41
###xml 291 297 289 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig2" ref-type="fig">Fig.&#160;2</xref>
###xml 356 357 354 355 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 594 595 592 593 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
To investigate whether the augmentation of cAMP release by PGF is mediated by either the EP2 or FP receptor, FPEP2 cells were treated with Butaprost and/or PGF in the presence/absence of specific antagonist for the EP2 receptor (AH6809; 10 mum) or FP receptor (AL-8810; 50 mum). As shown in Fig. 2C, antagonism of the EP2 receptor significantly decreased (P < 0.001) Butaprost-induced cAMP release in both groups (Butaprost only and Butaprost and PGF). In contrast, the FP receptor antagonist only abolished the potentiation of cAMP by PGF without altering basal and Butaprost-stimulated cAMP (P < 0.001).
###end p 41
###begin p 42
###xml 96 97 92 93 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q</sub>
###xml 144 145 136 137 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q</sub>
###xml 236 242 227 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig2" ref-type="fig">Fig.&#160;2</xref>
###xml 262 263 249 250 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q</sub>
###xml 397 398 384 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 533 534 516 517 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q</sub>
To assess if the PGF potentiation of Butaprost-stimulated cAMP is mediated by FP receptor-Galphaq coupling, FPEP2 cells were treated with Galphaq inhibitor (YM-254890; 1 mum) in the presence/absence of Butaprost and/or PGF. As shown in Fig. 2C, the use of Galphaq inhibitor significantly reduced the level of PGF and Butaprost-stimulated cAMP to the level observed in the Butaprost-treated cells (P < 0.001). These data indicate that, PGF potentiation of Butaprost-stimulated cAMP is mediated via the FP receptor activation of Galphaq.
###end p 42
###begin p 43
###xml 32 33 28 29 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q</sub>
###xml 172 178 168 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib7 bib26" ref-type="bibr">[7,26]</xref>
###xml 309 315 305 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig2" ref-type="fig">Fig.&#160;2</xref>
###xml 448 449 433 434 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">s</sub>
###xml 456 457 437 438 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q</sub>
###xml 810 811 789 790 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1123 1129 1102 1108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig2" ref-type="fig">Fig.&#160;2</xref>
PGF activated FP receptor-Galphaq coupling leads to activation of PLC that results in both IP release, to increase intracellular calcium and DAG release that activates PKC [7,26]. We assessed whether the PGF-mediated enhancement of Butaprost-stimulated cAMP was via the PLC-IP or PLC-PKC pathway. As shown in Fig. 2D, inhibition of PLC using the PLCbeta inhibitor U73122 (10 microM) abolished the augmentation shown by PGF demonstrating this Galphas-Galphaq cross-talk is mediated by PLC activation. In order to determine whether intracellular calcium or PKC activation mediate the observed cross-talk, the cells were incubated with specific IP3R blocker (2-APB; 40 mum) or PKC inhibitor (Ro-31-822; 1 mum) in the presence of Butaprost and/or PGF. Co-treatment of the cells with 2-APB significantly inhibited (P < 0.001) the PGF-mediated increase in Butaprost-induced cAMP release but had no effect on Butaprost treatment alone. Whereas inhibition of PKC had minimal effect on reducing the PGF-mediated augmentation of cAMP demonstrating that PGF-mediated increase in cAMP is via the accumulation of intracellular calcium (Fig. 2D).
###end p 43
###begin title 44
###xml 61 63 61 63 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
PGF-induced cAMP potentiation is mediated by intracellular Ca2+ transients and activation of the AC3 isoform in FPEP2 Ishikawa cells
###end title 44
###begin p 45
###xml 148 152 148 152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib27" ref-type="bibr">[27]</xref>
###xml 453 454 451 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 591 597 589 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig3" ref-type="fig">Fig.&#160;3</xref>
###xml 698 700 696 698 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
Intracellular calcium is known to modulate calcium sensitive isoforms of AC to enhance cAMP production via activation of calmodulin-CaMK-II pathway [27]. To determine whether the PGF-mediated enhancement of cAMP is regulated by the calcium-calmodulin pathway, chemical inhibitors against two calcium effectors were used. Inhibition of calcium pathway, using calmodulin antagonist (W7; 25 mum) or CaMK-II inhibitor (KN-93; 50 mum) significantly reduced (P < 0.001) the level of cAMP release seen in FPEP2 cells treated with the combination of Butaprost and PGF to Butaprost-stimulated level (Fig. 3A). These results indicate that PGF potentiation of Butaprost-stimulated cAMP is by the release of Ca2+ from intracellular stores leading to activation of calmodulin-CaMK-II pathway.
###end p 45
###begin p 46
###xml 384 388 384 388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib11" ref-type="bibr">[11]</xref>
###xml 464 465 460 461 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">s</sub>
###xml 472 473 464 465 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q</sub>
###xml 485 495 477 487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib12 bib13 bib14 bib28" ref-type="bibr">[12&#8211;14,28]</xref>
###xml 896 902 888 894 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig3" ref-type="fig">Fig.&#160;3</xref>
###xml 1055 1061 1047 1053 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig3" ref-type="fig">Fig.&#160;3</xref>
###xml 1303 1309 1295 1301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig3" ref-type="fig">Fig.&#160;3</xref>
###xml 1429 1430 1421 1422 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1603 1604 1591 1592 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q</sub>
###xml 1607 1609 1595 1597 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
To investigate which AC isoforms are present in FPEP2 cells, RT-PCR was performed using AC isoform-specific primers. We found that Ishikawa cells express mRNA for AC1, AC3, AC4, AC5, AC6, AC7, AC9 and the soluble AC (SAC), but not AC2 or AC8 isoforms (data not shown). Out of the eight isoforms expressed in Ishikawa cells two of them are known to be calcium stimulated (AC1 and AC3) [11]. Calcium-regulated AC isoforms have been suggested to be involved in Galphas-Galphaq cross-talk [12-14,28]. To identify which AC isoform is involved in the EP2-FP receptor cross-talk, siRNA designed to AC1 and AC3 were used to knockdown endogenous mRNA expression of the specific isoforms. After specific siRNA transfection into FPEP2 cells, quantitative real-time RT-PCR showed that AC1 and AC3 mRNA expressions were reduced by 76% and 70% respectively compared with scrambled sequence siRNA transfection (Fig. 3B). The specificity of the siRNA was also proven as both AC1 and AC3 siRNA inhibited the expression of their cognate targets without altering the other (Fig. 3B). After 48 h of siRNA transfection, cells were exposed to either Butaprost and/or PGF for 5 min. Thereafter, cells were lysed and subjected to cAMP analysis as described earlier to assess the functional effect of the knockdown. As shown in Fig. 3C, transfection with AC3 siRNA completely abolished the potentiation of Butaprost-stimulated cAMP by PGF significantly (P < 0.001) while AC1 siRNA transfection had no effect on cAMP accumulation. This result demonstrates that PGF can enhance Butaprost-stimulated cAMP via the FP receptor-Galphaq-Ca2+-calmodulin pathway by activating the calcium sensitive AC3 isoform.
###end p 46
###begin title 47
Gene array analysis
###end title 47
###begin p 48
###xml 497 504 497 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="tbl2" ref-type="table">Table&#160;2</xref>
Gene array analysis was used to identify downstream gene transcriptional changes influenced by PGF-enhanced Butaprost-stimulated cAMP signaling. Ishikawa FPEP2 cells were treated with vehicle, Butaprost and/or PGF for 8 h. RNA was extracted, hybridized to AB1700 gene chips, and subjected to gene array analysis. The analysis identified 34 genes whose expression was not regulated by PGF alone, but altered in response to Butaprost and PGF co-treatment compared to treatment with Butaprost alone (Table 2). For example SAT1 gene expression was enhanced from a 5.9 fold increase to a 7.5 fold increase, whereas cytochrome P450, family 26, subfamily A, polypeptide 1 (CYP26A1) gene expression was repressed from an 18.0 fold increase to a 12.3 fold increase. To determine whether the list contained genes with common functions the Gene Ontology database was used to group the genes into functional ontologies. Three functional groups were identified which were represented by 5 or more genes, those for cellular metabolism, immune response and excretion.
###end p 48
###begin title 49
###xml 64 65 60 61 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">s</sub>
###xml 72 73 64 65 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q</sub>
Butaprost-mediated SAT1 gene expression is potentiated by Galphas-Galphaq cross-talk
###end title 49
###begin p 50
###xml 170 171 166 167 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">s</sub>
###xml 178 179 170 171 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q</sub>
###xml 305 312 297 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="tbl2" ref-type="table">Table&#160;2</xref>
###xml 491 495 483 487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib34" ref-type="bibr">[34]</xref>
###xml 643 649 635 641 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig4" ref-type="fig">Fig.&#160;4</xref>
###xml 771 772 763 764 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1025 1026 1017 1018 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1272 1278 1264 1270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig4" ref-type="fig">Fig.&#160;4</xref>
Since our array analysis has demonstrated a unique subset of genes, whose expression induced by Butaprost was modulated by PGF, we next investigated the integrated Galphas-Galphaq cross-talk regulating downstream transcriptional activation by analyzing a candidate gene SAT1, selected from the gene list (Table 2). We focused on the regulation of this gene since it is known to be regulated by cAMP via the cAMP response element binding protein (CREB) that is located on its promoter region [34]. To study the temporal expression of this gene, FPEP2 Ishikawa cells were treated with vehicle, Butaprost and/or PGF for 4, 6 and 8 h. As shown in Fig. 4A, Butaprost treatment alone significantly increased expression of SAT1 at all time points compared to vehicle treatment (P < 0.001). No significant elevation of SAT1 gene expression was observed following PGF treatment alone. However, co-stimulation of FPEP2 cells with Butaprost and PGF enhanced the Butaprost-stimulated expression of SAT1 significantly at all time points (P < 0.001). To determine whether the PGF-mediated potentiation of SAT1 expression is mediated by the FP receptor, the cells were treated with the FP receptor antagonist (AL8810) in the presence/absence of Butaprost and/or PGF for 6 h. As shown in Fig. 4B, antagonism of the FP receptor completely abolished the potentiation of SAT1 expression by PGF without altering Butaprost-stimulated expression of SAT1. These data demonstrate that Butaprost-regulated expression of SAT1 is augmented by PGF-FP receptor coupling.
###end p 50
###begin p 51
###xml 54 55 50 51 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">s</sub>
###xml 62 63 54 55 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q</sub>
###xml 196 202 188 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig4" ref-type="fig">Fig.&#160;4</xref>
###xml 392 393 384 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
Since we have shown that AC3 is involved in the Galphas-Galphaq cross-talk in FPEP2 cells, we assessed if the same isoform is involved in PGF-mediated potentiation of SAT1 expression. As shown in Fig. 4C, ablation of AC3 expression reduced SAT1 mRNA expression in FPEP2 cells treated with the combination of Butaprost and PGF to the level observed following stimulation with Butaprost alone (P < 0.001). These data demonstrate that PGF-mediated potentiation of SAT1 mRNA expression is mediated by the EP2-FP receptor cross-talk via the FP receptor activation of the calcium sensitive AC3 isoform.
###end p 51
###begin title 52
Discussion
###end title 52
###begin p 53
###xml 203 214 203 214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib3 bib5 bib29 bib30" ref-type="bibr">[3,5,29,30]</xref>
###xml 214 215 214 215 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">.</italic>
###xml 664 670 664 670 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib7 bib18" ref-type="bibr">[7,18]</xref>
###xml 925 929 922 926 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib31" ref-type="bibr">[31]</xref>
There is mounting evidence to support a role for prostaglandins and their respective receptors in endometrial pathologies such as dysmenorrhoea, endometriosis, menorrhagia and endometrial adenocarcinoma [3,5,29,30]. Studies in our laboratory and others have used a reductionist approach to dissecting the signaling pathways following the activation of individual EP2 or FP receptors in numerous cell types. We have shown activation of the EP2 and FP receptors can lead to phosphorylation of ERK1/2 via the activation of c-Src and transphosphorylation of the epidermal growth factor receptor (EGFR) in Ishikawa cells and endometrial adenocarcinoma explants ex vivo [7,18]. In addition others have shown activation of the EP2 receptors can trigger the Wnt signaling pathway that involves phosphorylation of glycogen synthase kinase-3 (GSK-3) by Akt to activate beta-catenin mediated transcriptional activation in HEK 293 cells [31].
###end p 53
###begin p 54
###xml 57 61 57 61 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib32" ref-type="bibr">[32]</xref>
Prostanoid receptors are co-expressed in many cell types [32]. This suggests that co-activation of prostanoid receptors in the same cell could alter the physiological/pathophysiological gene expression profile and outcome. However, to our knowledge there have been no studies addressing the integrative signaling effects of the EP2 and FP receptors on signal transduction and gene expression. Here we show for the first time that co-activation of prostanoid receptors can alter the gene expression profile in endometrial adenocarcinoma cells stably expressing the EP2 and FP receptors. In addition to our knowledge this is the first study to investigate the cross-talk between the EP2 and FP receptors and the molecular mechanism underlying the intracellular signaling pathway in response to co-activation of both receptors.
###end p 54
###begin p 55
In order to investigate prostanoid integrative signaling, we stably transfected the EP2 receptor into Ishikawa cells stably expressing the FP receptor. Expression level of the EP2 receptor in FPEP2 cells was compared to the parental FPS32 cells using quantitative real-time RT-PCR, Western blot analysis and immunofluorescence microscopy confirming stable expression of EP2 receptor in FPEP2 cells localised to the perinuclear and plasma membrane. Introduction of the EP2 receptor had no effect on the expression profile of the other E-series receptors and of FP receptor which could be activated by prostanoid ligands in our study. Furthermore, the functionality of EP2 and FP receptors was also confirmed by the release of their respective secondary messengers, cAMP and IP in the presence of their respective ligands.
###end p 55
###begin p 56
###xml 708 709 704 705 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q</sub>
###xml 967 973 963 969 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig5" ref-type="fig">Fig.&#160;5</xref>
###xml 1115 1128 1111 1124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib12 bib13 bib14 bib27 bib28" ref-type="bibr">[12&#8211;14,27,28]</xref>
###xml 1493 1494 1485 1486 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">s</sub>
###xml 1501 1502 1489 1490 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q</sub>
Using the FPEP2 cells as a model system, we showed that Butaprost stimulation of FPEP2 cells gave a robust intracellular accumulation of cAMP while PGF-mediated FP receptor activation by its own had no effect on cAMP production. Interestingly we found that PGF could significantly enhance the cAMP accumulation in combination with Butaprost. Using specific receptor antagonists and small molecule chemical inhibitors of cell signaling we dissected the signaling pathways mediating the PGF-induced augmentation of cAMP in cells treated with the combination of ligands and have shown that the PGF-enhancement of cAMP observed in FPEP2 cells treated with Butaprost and PGF was induced via the FP receptor-Galphaq-mediated activation of IP via PLC. Following its release IP could activate its receptors (IPR) present on the endoplasmic reticulum (ER) membrane to promote intracellular calcium release and activation of calmodulin and CaMK-II as depicted schematically in Fig. 5. Numerous studies have shown that the CaMK-II pathway can activate calcium sensitive AC isoforms to regulate intracellular cAMP accumulation [12-14,27,28]. We identified AC1 and AC3 as calcium-regulated targets in our FPEP2 cells by RT-PCR analysis. Transfection studies using siRNA to abolish expression of AC1 or AC3 in FPEP2 cells revealed that the calcium sensitive AC3 (but not AC1) isoform is responsible for PGF-mediated potentiation of Butaprost-stimulated cAMP. These data suggest that the cAMP mediated Galphas-Galphaq cross-talk reported here is via the activation of the calcium sensitive isoform AC3.
###end p 56
###begin p 57
###xml 41 42 37 38 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">s</sub>
###xml 49 50 41 42 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q</sub>
###xml 113 120 105 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib12 bib13 bib14" ref-type="bibr">[12&#8211;14]</xref>
###xml 132 133 120 121 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">s</sub>
###xml 140 141 124 125 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q</sub>
###xml 179 183 163 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib13" ref-type="bibr">[13]</xref>
###xml 1144 1148 1125 1129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib33" ref-type="bibr">[33]</xref>
###xml 1300 1304 1281 1285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib34" ref-type="bibr">[34]</xref>
###xml 1476 1477 1453 1454 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">s</sub>
###xml 1484 1485 1457 1458 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q</sub>
###xml 1757 1761 1730 1734 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib35" ref-type="bibr">[35]</xref>
###xml 1948 1952 1921 1925 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib36" ref-type="bibr">[36]</xref>
###xml 1968 1972 1941 1945 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib37" ref-type="bibr">[37]</xref>
###xml 2029 2034 2002 2007 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">min/+</sup>
###xml 1807 1811 <span type="species:ncbi:10090">mice</span>
###xml 2000 2015 <span type="species:ncbi:10090">transgenic mice</span>
###xml 2035 2039 <span type="species:ncbi:10090">mice</span>
###xml 2041 2045 <span type="species:ncbi:10090">mice</span>
###xml 2172 2176 <span type="species:ncbi:10090">mice</span>
There has been other cAMP mediated Galphas-Galphaq cross-talk reported but only one with physiological relevance [12-14]. The Galphas-Galphaq cross-talk reported by Ostram et al. [13] had an important physiological consequence on regulation of the extracellular matrix in myocardium. The authors showed beta-adrenergic receptor mediated inhibition of collagen synthesis was further decreased by co-activation of angiotensin II receptor suggesting the cross-talk might play a role in inhibition of fibrosis in heart. In order to determine the integrative effects of receptor co-activation on gene expression, we performed whole genome array profiling in FPEP2 cells in response to Butaprost, PGF or the combination of Butaprost and PGF. Co-activation of FPEP2 cells with Butaprost and PGF enhanced or repressed a set of Butaprost (EP2 receptor) regulated genes. Analysis of the gene list for Gene Ontology annotations indicated functions in cellular metabolism, immune response and excretion. One of the genes identified, SAT1 is an important enzyme in polyamine metabolism, adding an acetyl group to aminopropyl ends of spermidine and spermine [33]. The promoter region of SAT1 lacks TATA box but has multiple binding sites for transcriptional factors including CREB, suggesting it is cAMP regulated [34]. We investigated the integrative signaling mediating the role of prostanoids on SAT1 expression in FPEP2 cells. We found that SAT1 is regulated by the cAMP mediated Galphas-Galphaq cross-talk via AC3, such that siRNA knockdown of the AC3 isoform completely inhibited the potentiation of Butaprost-stimulated SAT1 expression by PGF. SAT1 is a highly regulated enzyme and it is inducible by polyamines and has been shown to be involved in carcinogenesis [35]. A transgenic increase of SAT1 expression in mice showed a variety of defects such as hair loss, female infertility, impaired lipid metabolism and predisposition to develop pancreatitis [36]. Tucker et al. [37] showed SAT1-over producing transgenic mice bred with Apcmin/+ mice (mice predisposed to intestinal tumor formation) had an increase in incidence of intestinal tumors while crosses with SAT1 knockout mice led to 75% reduction in tumor load.
###end p 57
###begin p 58
###xml 191 195 187 191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib38" ref-type="bibr">[38]</xref>
###xml 242 246 238 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib39" ref-type="bibr">[39]</xref>
Although the role of SAT1 in endometrial pathologies with dysregulated prostanoids is unclear, SAT1 has been shown to have a direct effect on cell migration by binding with alpha9B1-integrin [38]. Moreover, in a recent study, Vlahakis et al. [39] have demonstrated that alpha9B1-integrin can bind to the vascular endothelial growth factor (VEGF) to promote angiogenesis. In light of these studies, SAT1 might play a role in pathologies of endometrium by directly promoting cell migration and an indirect enhancement of angiogenesis via alpha9B1-integrin.
###end p 58
###begin title 59
Conclusions
###end title 59
###begin p 60
###xml 119 120 115 116 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q</sub>
This study demonstrates that co-activation of the EP2 and FP receptors results in enhanced release of cAMP, in a Galphaq-calcium-dependent manner via the calcium sensitive AC3 isoform. Activation of this pathway modulates expression of genes involved in metabolism, immune response and excretion. Taken together our data suggest that when both EP2 and FP receptors are co-activated this leads to a unique integrative signaling pathway that modulates downstream gene expression of a subset of EP2 receptor induced genes.
###end p 60
###begin title 61
Acknowledgements
###end title 61
###begin p 62
This study was supported by MRC core funding to HNJ (U.1276.00.004.00002.01) and by the South African MRC to AK.
###end p 62
###begin title 63
References
###end title 63
###begin p 64
###xml 301 302 301 302 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 313 314 313 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 880 881 879 880 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 891 892 890 891 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 907 908 906 907 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1073 1074 1072 1073 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
EP2 and FP receptor analysis in FPS32 and FPEP2 cells. Relative mRNA expression of (A) EP2 receptor (B) EP1, EP3, EP4 and FP receptors as determined by quantitative real-time RT-PCR analysis in FPS32 and FPEP2 cells. Expression levels in FPEP2 clones are expressed as fold increase above FPS32 cells (n = 4; ***, P < 0.0001). (C) Protein expression of FP and EP2 receptors normalized for loading against ss-actin and expressed as fold increase above FPS32 cells as determined by Western blot analysis. (D) Localization of the FP (FPR) and EP2 (EP2R) receptor in FPS32 and FPEP2 cells as determined by immunofluorescence microscopy. Control cells (C) were incubated with preadsorbed primary antibody using specific blocking peptides. (E) The effect of 5 and 10 min treatments with vehicle or Butaprost on cAMP release in FPS32 and FPEP2 cells as determined by cAMP ELISA analysis (n = 4; **, P < 0.001; ***, P < 0.0001). (F) The effect of 60 min PGF stimulation on IP response in FPS32 and FPEP2 cell lines. Data are expressed as fold increase above non-stimulated samples (n = 5).
###end p 64
###begin p 65
###xml 72 73 68 69 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q</sub>
###xml 161 165 157 161 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;&#160;10</sup>
###xml 171 174 167 170 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;&#160;6</sup>
###xml 215 219 210 214 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;&#160;10</sup>
###xml 225 228 220 223 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;&#160;6</sup>
###xml 369 370 363 364 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 472 473 466 467 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 667 668 657 658 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q</sub>
###xml 702 703 692 693 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 921 922 905 906 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 932 933 916 917 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
PGF enhances Butaprost-stimulated cAMP production via FP receptor-Galphaq coupling and PLC activation. (A) IP release in FPEP2 cells after treatment with PGF (10- 10 to 10- 6 M) or (5 muM) Butaprost alone or PGF (10- 10 to 10- 6 M) and Butaprost (5 muM) together for 60 min as determined by an IP assay. Data are expressed as fold increase above non-stimulated sample (n = 4). (B) cAMP accumulation in FPEP2 cells after 5 min treatment with vehicle, Butaprost and/or PGF (n = 4). (C) cAMP accumulation in FPEP2 cells treated with vehicle, Butaprost and/or PGF in the presence/absence of the EP2 receptor antagonist (AH6809), FP receptor antagonist (AL-8810) or Galphaq inhibitor (YM-254890) for 5 min (n = 4). (D) cAMP in cells treated with vehicle Butaprost and/or PGF or Butaprost and/or PGF together with the PLC inhibitor (10 microM U73122), IP3-R blocker (40 mum 2-APB) or PKC inhibitor (1 mum Ro-31-822) for 5 min (n = 4; **, P < 0.001).
###end p 65
###begin p 66
###xml 291 292 291 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 446 447 446 447 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 610 611 610 611 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 621 622 621 622 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
PGF potentiates Butaprost-stimulated cAMP through calmodulin-CaMK-II pathway by activating AC3 isoform in FPEP2 cells. (A) cAMP accumulation in FPEP2 cells after 5 min treatment with vehicle, Butaprost and/or PGF in the presence/absence of inhibitors for calmodulin (W7) or CaMK-II (KN-93) (n = 4). (B) Real-Time RT-PCR analysis of AC1 and AC3 in FPEP2 cells transfected with specific AC siRNA compared to the control siRNA (scrambled sequence) (n = 4). (C) cAMP accumulation in control, AC1 or AC3 knockdown FPEP2 cells after 5 min treatment with vehicle, Butaprost and/or PGF as determined by cAMP analysis (n = 4; **, P < 0.001).
###end p 66
###begin p 67
###xml 224 225 224 225 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 401 402 401 402 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 548 549 548 549 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 561 562 561 562 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
PGF potentiates Butaprost-regulated SAT1 gene expression in FPEP2 cells via the calcium sensitive AC3 isoform. (A) Relative expression of SAT1 in FPEP2 cells after 4, 6 and 8 h treatments with vehicle, Butaprost and/or PGF (n = 4). (B) Relative expression of SAT1 in FPEP2 cells after 6 h treatment with vehicle, Butaprost and/or PGF in the absence or presence of the FP receptor antagonist (AL8810) (n = 4). (C) Relative expression of SAT1 in FPEP2 cells transfected with siRNA and subsequently treated for 6 h with vehicle, Butaprost and/or PGF (n = 4); (**, P < 0.001).
###end p 67
###begin p 68
###xml 6 7 2 3 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q</sub>
###xml 91 92 83 84 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">s</sub>
###xml 304 305 292 293 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q</sub>
###xml 450 452 438 440 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
Galphaq-mediated potentiation of Butaprost-induced cAMP release. Butaprost activates Galphas-coupled EP2 receptors resulting in a rapid increase in intracellular cAMP accumulation while PGF by itself does not alter cAMP production. However, co-treatment of the cells with both ligands leads to the Galphaq-mediated activation of PLC and release of IP3 from the plasma membrane. Subsequently, IP3 via the IP3 receptor (IP3R) mediates the release of Ca2+ from intracellular stores leading to calmodulin-CaMK-II dependent potentiation of cAMP release via the calcium sensitive AC3 isoform and modulation of gene transcription such as SAT1.
###end p 68
###begin p 69
Taqman primers and probes sequences for EP1, EP2, EP3, EP4, FP receptors, AC1, AC3, SAT1 and 18S.
###end p 69
###begin p 70
Genes differentially expressed by Butaprost treatment only and modulated in combination with PGF treatment.
###end p 70

